Apellis Pharmaceuticals, Inc.
APLS
$23.27
-$0.22-0.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -42.15M | -92.23M | -36.35M | -57.45M | -37.66M |
| Total Depreciation and Amortization | 446.00K | 446.00K | 447.00K | 457.00K | 449.00K |
| Total Amortization of Deferred Charges | 614.00K | 591.00K | 587.00K | 658.00K | 238.00K |
| Total Other Non-Cash Items | 27.20M | 27.37M | 26.31M | 27.48M | 34.81M |
| Change in Net Operating Assets | 18.34M | 10.40M | 28.37M | 62.95M | -6.18M |
| Cash from Operations | 4.45M | -53.41M | 19.36M | 34.10M | -8.34M |
| Capital Expenditure | -49.00K | -8.00K | -20.00K | 0.00 | -90.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -49.00K | -8.00K | -20.00K | 0.00 | -90.00K |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 365.45M |
| Total Debt Repaid | -- | -- | -- | 1.59M | -- |
| Issuance of Common Stock | 6.56M | 281.00K | 1.64M | 2.56M | 5.16M |
| Repurchase of Common Stock | 0.00 | -7.00K | -15.00K | -14.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -5.63M | -1.59M | -328.12M |
| Cash from Financing | 6.56M | 274.00K | -4.00M | 2.54M | 42.49M |
| Foreign Exchange rate Adjustments | 685.00K | 359.00K | -965.00K | 173.00K | 342.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.64M | -52.79M | 14.38M | 36.81M | 34.40M |